With the increasing number of options for the treatment of moderate‐to‐severe atopic
dermatitis, clinicians need guidance on a practical approach to selecting a systemic agent …

Atopic dermatitis is a heterogeneous disease and resists classification. In this review, we
discuss atopic dermatitis nomenclature and identify morphologic phenotypes, which will …

Background Dupilumab blocks the shared receptor component for interleukin (IL)‐4 and IL‐
13. It is approved in the USA for patients aged≥ 12 years with moderate‐to‐severe atopic …

Importance The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled,
moderate to severe atopic dermatitis (AD). Objective To assess the efficacy and safety of …

Background Tralokinumab, a fully human IgG4 monoclonal antibody that specifically binds
with high affinity to interleukin‐13, effectively reduces moderate‐to‐severe atopic dermatitis …

Keratoconus is a progressive eye disorder primarily affecting individuals in adolescence and
early adulthood. The ectatic changes in the cornea cause thinning and cone-like steepening …

This is the English version of the Clinical Practice Guidelines for the Management of Atopic
Dermatitis 2021. Atopic dermatitis (AD) is a disease characterized by relapsing eczema with …

Background Additional long-term treatments are needed for moderate-to-severe atopic
dermatitis (AD). An ongoing, open-label, 5-year extension trial, ECZTEND (NCT03587805) …

Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus, characterized by
recurrent eczema with exacerbations and remissions. AD impairs patients' QOL and places …

Importance Clinical trials of dupilumab for atopic dermatitis (AD) have reported an increased
incidence of conjunctivitis in patients who received dupilumab compared with those who …